LONDON, July 27 (Reuters) - GlaxoSmithKline plans275 million pounds ($361 million) of new investments at threedrug manufacturing sites in Britain, signalling its confidencein the country despite last month's vote to leave the EuropeanUnion. (Reporting by Ben Hirschler; Editing by David Holmes)
Japan accepts GSK's regulatory filing for momelotinib for blood cancer
(Alliance News) - GSK PLC on Monday reported regulatory progress for momelotinib, as Japan's Ministry of Health, Labour & Welfare accepted a review for the blood cancer-focused drug.
Read more